Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Evandro de Azambuja



Jules Bordet Institute

Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium.

Dr de Azambuja earned his first PhD from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, in May 2007 and his second PhD from the Université Libre de Bruxelles (U.L.B) in December 2015.

His principal interest in oncology is breast cancer, especially in the adjuvant/neoadjuvant settings. He is deeply involved in the conduct of large phase III trials in breast cancer such as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib) and APHINITY (trastuzumab with or without pertuzumab) and – in the neoadjuvant setting – the LORELEI trial which tests the efficacy of PI3K inhibition.  He is also greatly engaged in studies concerning cancer toxicity of new drugs in oncology as well as in long-term follow-up of patients enrolled in clinical trials with focus in cardiotoxicity.  Within the latter context, he was a co-author of guidelines on treatment-related cardiac toxicity by the European Society of Medical Oncology (ESMO) and the European Society of Cardiology (ESC).  He was past Chair of the survivorship group of the Belgian Society of Medical Oncology (BSMO).

Dr. de Azambuja was a member of the ESMO Young Oncologists Committee (YOC), a faculty member of the ESMO Leaders Generation Programme launched in 2016 and he was also appointed as a Breast Faculty Member of ESMO in 2017 and a Board Member of the Belgian Society of Medical Oncology (BSMO) since 2015.

He is currently Fellowship & Award Committee Chair (2018-2019) of ESMO and also serves as member of its Executive Board.

Dr. de Azambuja is also a member of the American Society of Clinical Oncology (ASCO) and the Belgian Society of Medical Oncology (BSMO).  He is actively involved in editorial boards of the Journal of Clinical Oncology (JCO), “ESMO Open – Cancer Horizons”, and ESMO Perspective.

He has (co)-authored approximately 150 peer-reviewed articles and 9 book chapters.

He has been a member of Education and Scientific Committees of the ESMO, EBCC and ECCO meetings.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings